

1 **A low pre-existing anti-NS1 humoral immunity to DENV is associated with microcephaly**
2 **development after gestational ZIKV exposure**

3
4 Sebastián Castro-Trujillo¹, William R. Mejía^{2,3}, Katherine Segura^{1,4}, Rocío Vega^{2,3}, Doris
5 Salgado^{2,3}, Carlos E. Fonseca³, Ángela M. Ortiz^{2,3}, Federico Perdomo-Celis⁴, Irene Bosch⁵, Carlos
6 F. Narváez^{1,2}.

7
8 1 División de Inmunología, Programa de Medicina, Facultad de Ciencias de la Salud,
9 Universidad Surcolombiana, Neiva 41001, Huila, Colombia.

10 2 Área de Pediatría, Departamento de Ciencias Clínicas, Facultad de Ciencias de la Salud,
11 Universidad Surcolombiana, Neiva, Huila, Colombia.

12 3 Servicio de Pediatría, Hospital Universitario de Neiva, Neiva, Huila, Colombia.

13 4 Instituto de Genética Humana, Facultad de Medicina, Pontificia Universidad Javeriana,
14 Bogotá, Colombia.

15 5 Institute for Medical Engineering and Science, Massachusetts Institute of Technology (MIT),
16 Cambridge, Massachusetts, USA.

17

18

19 Address for correspondence:

20

21 Carlos F. Narváez, MD, PhD, División de Inmunología, Facultad de Ciencias de la Salud,
22 Universidad Surcolombiana. Calle 9 # 14 – 03, Barrio Altico, Neiva 41001, Huila, Colombia.

23 E-mail: cfnarvaez@usco.edu.co

24

25

26

27

28

29

30

31

32

33 Short title: Relationship between the NS1 humoral response and the congenital Zika syndrome.

34

35

36

37

38 Keywords: Zika; Dengue; NS1; Microcephaly; IgG; IgM; ELISA.

39

40

41 **ABSTRACT**

42

43 **Background:** Gestational Zika virus (ZIKV) infection is associated with the development of
44 congenital Zika syndrome (CZS), which includes microcephaly and fetal demise. The magnitude
45 and quality of orthoflavivirus-specific humoral immunity have been previously linked to the
46 development of CZS. However, the role of ZIKV NS1-specific humoral immunity in mothers and
47 children with prenatal ZIKV exposure and CZS remains undefined. In addition, considering that
48 most of the at-risk population lives in dengue virus (DENV)-endemic areas, it is not clear what is
49 the association between pre-existing DENV NS1-specific humoral immunity and CZS.

50 **Methods:** Here, we studied 328 mothers and children with a clinical diagnosis and seropositivity
51 for ZIKV infection during pregnancy, included during the 2015-2016 ZIKV epidemic in
52 Colombia. We also performed clinical evaluation and pediatric neurological follow-up. The
53 relative levels of circulating NS1-specific IgM and IgG against ZIKV and DENV were evaluated
54 in mothers and children, and the association with the development of microcephaly was analyzed.

55 **Results:** DENV and ZIKV IgG-NS1 antibodies in pregnant women were placentally transferred,
56 and this passage and its duration in children depended on the maternal levels of the antibodies. We
57 reported that higher concentrations of pre-existing DENV, but not ZIKV IgG-NS1 antibodies,
58 were associated with a reduced risk of CZS-related microcephaly. Also, we observed that the IgM-
59 NS1 response presents as long-term and has a minor association with poor outcomes.

60 **Conclusions:** The development of microcephaly in children prenatally exposed to ZIKV is
61 associated with low plasma levels of placentally transferred, pre-existing DENV IgG-NS1
62 antibodies. These data are compatible with a protective role of anti-NS1 IgG antibodies against
63 ZIKV infection during pregnancy and highlight the promising role of NS1 as an orthoflavivirus
64 vaccine target in high-risk populations.

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81 INTRODUCTION

82 Zika Virus (ZIKV) is an arbovirus transmitted to humans through the bite of *Aedes* mosquitoes
83 [1]. Like other orthoflaviviruses (such as dengue virus [DENV]), ZIKV is an enveloped virus with
84 a positive-sense, single-stranded RNA genome that codifies for three structural proteins (E, preM,
85 and C) and seven nonstructural proteins [2]. Zika virus is a re-emerging pathogen that in 2022 had
86 affected at least 89 countries worldwide, primarily in tropical and subtropical regions [3]. Between
87 October 2015 and July 2016, active autochthonous transmission of ZIKV was confirmed in
88 Colombia, leading to a nationwide epidemic declaration [4]. In February 2016, the World Health
89 Organization (WHO) declared ZIKV infection a public health emergency of international concern
90 [3], given the link between ZIKV infection during pregnancy and subsequent birth defects [5].
91 Indeed, although ZIKV infection is asymptomatic in most cases or courses as a self-limited and
92 mild disease [6], when infection occurs during pregnancy, ZIKV can be vertically transmitted,
93 resulting in spontaneous abortion or the development of congenital Zika syndrome (CZS) [6]. This
94 neonatal syndrome includes microcephaly, intracranial calcifications, ophthalmologic
95 abnormalities, and neurodevelopmental disorders [7]. In addition, infants with CZS may have a
96 case fatality rate of 10% within the first years of life [8]. In Colombia, microcephaly prevalence
97 increased from 2.1 per 10,000 live births in 2015 to 9.6 in 2016, supporting the association between
98 reported ZIKV infections and the occurrence of this clinical entity [9].

99

100 The mechanisms responsible for the development of CZS are not fully understood. While it is
101 known that ZIKV can infect and induce the death of human neural progenitor cells [10,11], tissue
102 damage may also be associated with an exacerbated immune response triggered by the infection
103 [12–14]. Furthermore, the humoral immune response against ZIKV and pre-existing immunity to
104 orthoflaviviruses may play protective or pathogenic roles in CZS [15]. Indeed, previous studies
105 have shown that neutralizing human antibodies directed to the ZIKV E protein can protect against
106 ZIKV replication and fetal demise in mice [16]. In contrast, pre-existing DENV-specific antibodies
107 in mice infected with ZIKV during pregnancy may enhance vertical ZIKV transmission, resulting
108 in microcephaly [17]. It is worth noting that while there has been extensive research on the humoral
109 response to the ZIKV and DENV E proteins, the response to the NS1 protein has not been studied
110 as extensively. This protein is highly immunogenic [18] and is associated with severe disease as
111 well as placental dysfunction [19]. A considerable proportion of the antibodies elicited by ZIKV
112 and DENV are targeted toward NS1 [20–22]. These antibodies exhibit lower cross-reactivity than
113 those directed to the E protein of related orthoflaviviruses, particularly DENV, which makes them
114 a valuable tool in the diagnosis [23]. In addition, anti-ZIKV NS1 antibodies decrease the risk of
115 antibody-dependent enhancement of infection [20,24], highlighting their role in antibody-
116 mediated protection against disease and as an optimal target in vaccine development. In keeping
117 with these data, previous studies have suggested that anti-ZIKV NS1 antibodies derived from adult
118 samples have a protective role against ZIKV disease [24,25]. Moreover, it was demonstrated that
119 antibodies recognizing cell-surface NS1 confer protection against ZIKV in pregnant mice [26].
120 However, it is unknown the role of anti-DENV NS1 antibodies in CZS.

121

122 Previous research has examined the link between the cellular immune response in mothers and
123 children and the development of CZS [27,28]. However, the connection between pre-existing
124 humoral immunity in mothers and CZS in their children remains unexplored. Particularly, it is
125 unknown whether anti-ZIKV NS1 humoral immunity in mothers and children with prenatal ZIKV
126 exposure is associated with CZS, especially in severe forms such as microcephaly. In addition,
127 since most of the at-risk population lives in dengue-endemic areas, it is essential to determine the
128 association between pre-existing anti-DENV NS1 antibodies and children and CZS development.
129 To investigate these aspects, we evaluated the levels of anti-NS1 IgM and IgG antibodies against
130 ZIKV and DENV in mothers and their offspring exposed to ZIKV during pregnancy. We observed
131 the transplacental passage of anti-NS1 IgG (but not IgM) antibodies from ZIKV and DENV, with
132 an expected clearance rate. In addition, we found a relationship between the levels of pre-existing
133 anti-NS1 humoral immunity to DENV and the occurrence of CZS-related microcephaly.

134

135 **METHODS**

136 **Ethics statement**

137 The study adhered to the principles of the Declaration of Helsinki and received approval from the
138 Ethics, Bioethics, and Research Committee of the Hospital Universitario Hernando Moncaleano
139 Perdomo in Neiva, Huila, Colombia (No. 004-007, April 19, 2016) and from the Ethics and
140 Research Committee of clínica ESIMED (Minute No. 007 dated September 14, 2016). All
141 participating mothers provided written informed consent for themselves and their children.

142

143 **Participants, samples, and pediatric follow-up**

144 A multicenter study was conducted including two independent cohorts with a total of 436
145 participants: the Hospital Universitario Hernando Moncaleano Perdomo cohort (n=272; mothers
146 and children), and the clínica ESIMED cohort (n=164; mothers and children), both located in
147 Neiva, southern Colombia, a hyper-endemic region for dengue [29]. We included mother/child
148 binomials with the antecedent of gestational exposure to ZIKV during the 2015-2016 Zika
149 epidemic. Exposure to ZIKV was defined as the presence of plasma anti-ZIKV NS1 IgG antibodies
150 in the mothers, accompanied by signs and symptoms of Zika disease during pregnancy at the peak
151 of the epidemic period. In all cases, TORCH syndrome (Toxoplasmosis, Other infections [such as
152 syphilis and HIV], Rubella, Cytomegalovirus, Herpes simplex) was ruled out by serological or
153 molecular testing. The study inclusion time was 0.2 to 19 months after the child's birth. At
154 enrollment, a blood sample was obtained simultaneously from all mothers and their infants (4 or
155 2 mL, respectively, collected in ethylenediaminetetraacetic acid-containing tubes). Plasma was
156 isolated through centrifugation at 200 x g for 5 minutes and stored at -80°C until analysis.
157 Neurological, speech therapy, and ophthalmological assessments were conducted for 113 children
158 up to 12 months after enrollment. The children's cognitive, language, and motor development were
159 evaluated with the Bayley-III child development scale and applied by a pediatric neurologist
160 specialist. Neurodevelopment alteration was defined as <85 points in any of the parameters

161 evaluated [30]. The complete characterization of neurological disturbances in these children can
162 be found elsewhere [31]. The study chart flow is presented in **Figure 1**.

163

164 **Measurement of plasma anti-NS1 IgM and IgG antibodies to ZIKV and DENV**

165 Indirect enzyme-linked immunosorbent assays (ELISA) based on recombinant whole NS1 protein
166 of ZIKV (Surinam strain, No. ZIKV-NS1) and a mix of the four NS1 DENV serotypes (DENV-1
167 Nauru/Western Pacific/1974, DENV-2 Thailand/16681/84, DENV-3 Sri Lanka D3/H/IMTSSA/
168 SRI/2000/1266 and DENV-4 Dominica/814669/1981) were used to evaluate the relative levels of
169 IgM and IgG antibodies in plasma samples (here referred to as IgG-NS1 or IgM-NS1), as
170 previously reported [32,33]. Samples obtained before 2014 from healthy individuals serologically
171 without exposure to either ZIKV or DENV were used as a negative control. Based on the negative
172 control, a detection limit of 0.27 and 0.36 optical densities (OD 450 nm) was established for anti-
173 NS1 IgM and IgG, respectively. Additionally, samples from convalescent patients with confirmed
174 ZIKV or DENV infection were included as a positive control. Anti-NS1 IgM and IgG antibodies
175 are reported as a positivity rate (percent of samples with OD 450 nm above the detection limit)
176 and relative levels (raw OD 450 nm values). All samples were evaluated in duplicate. Inter-plate
177 variability in the positive and negative controls was lower than 15%.

178

179 **Statistical Analysis**

180 Statistical analysis was performed with GraphPad Prism version 10. Quantitative analyses are
181 presented as medians and range. Frequency analyses were done using Fisher's exact test. The
182 Mann-Whitney and Wilcoxon tests were used for unpaired and paired analyses of the two groups,
183 respectively. Three or more independent groups were compared with Kruskal-Wallis and Dunn's
184 post-hoc tests. The correlation between variables was determined using the Spearman rank test.
185 The cutoff of DENV1-4/ZIKV IgG-NS1 ratio to predict microcephaly outcome was evaluated
186 using receiver operating characteristic (ROC) curve analyses. The better cutoff was chosen using
187 the Youden J Index (sensitivity + specificity - 1). A p-value <0.05 was considered significant. When
188 comparing IgM or IgG values, statistical analysis was performed only if the median level of any
189 group was above the limit of detection of the assay.

190

191 **RESULTS**

192 **Characteristics of the study cohort**

193 We included 218 mother and child pairs with clinical suspicion of prenatal ZIKV exposure. From
194 them, 190 had available clinical records and plasma samples. In turn, 164 mothers were positive
195 for IgG-NS1 ZIKV (**Figure 1**). Clinical follow-up was performed in 113 children. From them, 67
196 cases presented CZS: 17 developed microcephaly, 14 had ocular abnormalities, and 36 exhibited
197 only neurodevelopmental impairment (**Figure 1**). In 51 normocephalic infants, clinical follow-up
198 could not be performed. The clinical and demographic characteristics of the study cohort are shown

199 in **Table 1**. We grouped the participants as those without or with microcephaly. We did not observe
200 differences in the age of mothers from both groups (**Table 1**). However, consistent with the link
201 between ZIKV infection during the first trimester of pregnancy and microcephaly [34], in our
202 cohort, a higher proportion of cases of microcephaly occurred after ZIKV infection in the first
203 trimester (**Table 1**). In contrast, most cases of neurodevelopment and ocular alterations, such as
204 optical nerve hypoplasia and chorioretinitis, occurred after ZIKV infection during the second
205 trimester (**Supplementary Table 1**). We did not observe differences in the gestational age at birth,
206 in the clinical manifestations of suspected ZIKV infection in the mothers (including fever,
207 exanthema, and myalgias/arthralgias), and in the biological sex of the infants between those with
208 versus without microcephaly (**Table 1**).

209

210 **Placental transfer of ZIKV and DENV IgG-NS1 antibodies**

211 The dynamic of the humoral response to ongoing gestational ZIKV infection, as well as pre-
212 existing antibodies against DENV, remains unclear. Thus, we evaluated the plasma levels of ZIKV
213 and DENV IgM-NS1 and IgG antibodies in pregnant mothers and their newborns to determine the
214 transfer of these antibodies across the placenta and their temporal kinetics. Consistent with the
215 absence of ongoing or recent ZIKV or DENV infection at the time of sample collection, overall,
216 there were low or undetectable levels of IgM-NS1 both in mothers and children (**Figure 2A** and
217 **B; Supplementary Figure 1A**). This was also reflected in a poor correlation between IgM-NS1
218 in mothers and children (**Figure 2A** and **B**). Moreover, consistent with the lack of transplacental
219 passage of IgM [35], in some mothers with detectable levels of DENV IgM-NS1, these values
220 were not observed in their children (**Figure 2B**).

221

222 In contrast to IgM-NS1, there was a high positivity rate of IgG-NS1, a pattern consistent with the
223 high levels of endemic DENV transmission in this population [29]. As expected, the levels were
224 higher in the mothers than in the children (**Supplementary Figure 1B**). In addition, we observed
225 higher levels of DENV than ZIKV IgG-NS1 in mothers and children (**Supplementary Figure**
226 **1B**). It is known that placental transport of IgG depends on maternal levels [35]. In keeping with
227 this notion, we observed a positive correlation between IgG-NS1 in mothers and children, but the
228 strength of association was higher for DENV IgG-NS1 (**Figure 2C** and **D**). Consistent with the
229 kinetics of clearance of maternally acquired anti-orthoflavivirus IgG [36,37], the levels of ZIKV
230 and DENV IgG-NS1 declined in the infants predominantly from the sixth month of age onward,
231 nearly disappearing by the eighth month (**Figure 2E** and **F**). Of note, in children before six months
232 of age, the frequency of undetectable IgG-NS1 was significantly higher for ZIKV than for DENV
233 (69% vs. 30%, $p < 0.001$), indicating that a significant proportion of infants could be susceptible to
234 ZIKV reinfection early after birth. In contrast, the levels of these antibodies remained relatively
235 stable in the mothers (**Figure 2E** and **F**).

236

237 We also evaluated the impact of the time of ZIKV exposure on the levels of DENV and ZIKV
238 IgG-NS1. As such, we compared the antibody levels in samples from mothers and children

239 exposed to ZIKV during the first versus the third trimester of pregnancy. The mothers who were
240 exposed to ZIKV in the third trimester had significantly higher levels of DENV, but not ZIKV,
241 IgG-NS1 than those exposed in the first trimester (**Supplementary Figure 2A and B**), reflecting
242 the decay of DENV-specific antibody levels in the latter. A similar trend was observed for the
243 children (**Supplementary Figure 2C and D**). These data also indicate different dynamics and/or
244 sources of DENV- and ZIKV-specific antibodies. Indeed, we did not observe a correlation between
245 ZIKV and DENV IgG-NS1 antibody levels in plasma from mothers ($\rho=-0.05$; $p=0.45$) or
246 children ($\rho=0.004$; $p=0.95$). These results are likely related to the modest effect of prior DENV
247 infections on the breadth and magnitude of ZIKV-reactive memory B cell responses [38]. In
248 summary, these findings confirm the passive transfer of maternal anti-orthoflavivirus IgG-NS1
249 (but not IgM-NS1) antibodies and their subsequent clearance around the sixth month after birth.

250

251 **Poor association between ZIKV and DENV IgM-NS1 antibodies and CZS-related** 252 **microcephaly**

253 We next evaluated the relationship between ZIKV and DENV IgM-NS1 antibodies and the
254 development of microcephaly in children with CZS. Consistent with the low positivity rate in most
255 of the cases (**Figure 2A and B; Supplementary Figure 1A**), we did not observe significant
256 differences in ZIKV or DENV IgM-NS1 in the mothers of children with microcephaly versus those
257 without microcephaly, both in terms of the positivity rate (**Figure 3A**), or the relative plasma levels
258 (**Figure 3B**). In contrast, we observed that children with microcephaly exhibited a higher
259 seropositivity rate for ZIKV IgM-NS1 than those without microcephaly (**Figure 3C**). This
260 suggests a long-lasting IgM response in children with microcephaly, considering the early prenatal
261 exposure to ZIKV. However, the plasma levels of these antibodies (as well as those against DENV)
262 in general were below the detection limit (**Figure 3D**). Thus, overall, there is a minor association
263 between the IgM-NS1 response and the development of CZS-related microcephaly, and the ZIKV
264 IgM-NS1 response is long-lasting in a fraction of the children.

265

266 **Low pre-existing DENV IgG-NS1 is associated with CZS-related microcephaly**

267 We examined the association between orthoflavivirus IgG-NS1 antibody levels in mothers and
268 children and the development of microcephaly. We observed that mothers of children with
269 microcephaly had a lower positivity rate for DENV IgG-NS1 in comparison with those without
270 microcephaly (**Figure 4A**). Of note, this comparison was not performed for ZIKV IgG-NS1 since
271 positivity for this test was a study inclusion criterion. When we evaluated the relative levels of
272 IgG-NS1, we observed significantly lower levels of DENV, but not ZIKV, antibodies in mothers
273 of children with microcephaly relative to those without microcephaly (**Figure 4B**). In addition, we
274 employed the DENV/ZIKV IgG-NS1 ratio to measure the predominant viral-specific humoral
275 response. This analysis indicated that mothers of children with microcephaly had a lower
276 DENV/ZIKV IgG-NS1 ratio in comparison with those without microcephaly (**Figure 4C**).
277 Interestingly, a ROC curve analysis indicated that the DENV/ZIKV IgG-NS1 ratio in samples from
278 the mothers is robust in discriminating between both groups of children (**Figure 4D**).

279

280 We also evaluated the association between IgG-NS1 in plasma from the children exposed
281 prenatally to ZIKV and the risk of microcephaly. Of note, the samples from children who
282 developed microcephaly were obtained at an older age (median [range] of 8.2 months [4-15]) than
283 those without microcephaly (median [range]: 6 months [1-19]; $P=0.001$). Thus, considering the
284 clearance of maternally-transferred antibodies beyond 6 months of age (**Figures 2E and F**) and
285 that passively transferred antibodies depended on maternal levels (**Figure 2C and D**), it was
286 expected observe that children with microcephaly had a lower positivity rate for DENV IgG-NS1
287 (**Figure 4E**), as well as lower relative levels of DENV-specific antibodies (**Figure 4F**), in
288 comparison with those without microcephaly. No differences were obtained for ZIKV IgG-NS1
289 antibodies (**Figure 4E and F**). The DENV/ZIKV IgG ratio analysis abrogates the bias introduced
290 by the difference in the age of children with and without microcephaly. We observed a significantly
291 lower DENV/ZIKV IgG-NS1 ratio in children with microcephaly in comparison with non-
292 microcephalic children (**Figure 4G**), and this ratio could discriminate between both groups of
293 children (**Figure 4H**).

294

295 Finally, we evaluated the levels of DENV and ZIKV IgM/IgG-NS1 in mothers and children
296 without microcephaly but who developed neurodevelopmental or ocular alterations and compared
297 them with those who did not develop CZS. Overall, we did not detect DENV and ZIKV IgM-NS1
298 in all the groups analyzed (**Supplementary Figure 3A and C**). Moreover, when we evaluated IgG-
299 NS1, contrary to what we observed for microcephaly cases, we obtained comparable levels of
300 these antibodies in mothers of children with neurodevelopmental or ocular alterations relative to
301 those without CZS (**Supplementary Figure 3B**). Mothers from children with neurodevelopmental
302 alterations had even significantly higher DENV IgG-NS1 antibodies than those from the no CZS
303 group (**Supplementary Figure 3B**). A similar non-significant trend was obtained in the children
304 (**Supplementary Figure 3D**).

305 In summary, low levels of pre-existing DENV IgG-NS1 antibodies are associated with the
306 development of microcephaly, but not neurodevelopmental or ocular alterations, in children with
307 CZS.

308

309 **DISCUSSION**

310 Developing safe and effective immunization strategies for women of reproductive age living in
311 orthoflavivirus endemic areas is a public health priority given the risks associated with the vertical
312 transmission of ZIKV [15]. In addition, identifying immune correlates of protection against CZS
313 is highly needed. Here, we observed that pre-existing DENV IgG-NS1 antibodies in pregnant
314 women are placentally transferred to their children, and this passage depends on the maternal levels
315 of the antibodies. In addition, in the setting of ZIKV infection during pregnancy, higher levels of
316 these antibodies are associated with a reduced risk of CZS-related microcephaly but not with the
317 occurrence of neurodevelopmental or ocular alterations. In contrast, a minor association was
318 observed for the IgM-NS1 response, which is most likely explained by the absence of

319 transplacental passage of this isotype [35]. Consistent with these data, a previous study that
320 prospectively followed a cohort of 1,453 adults in dengue-endemic areas demonstrated that a two-
321 fold increase in IgG titers against DENV NS1 is associated with a 9% reduction in the risk of
322 ZIKV infection and symptoms [39]. Thus, pre-existing immunity directed to the NS1 protein of
323 orthoflaviviruses seems to play a protective role against ZIKV infection and CZS-related
324 microcephaly.

325
326 Due to its absence in viral particles, NS1 is usually not considered a vaccine target to induce
327 humoral responses against orthoflaviviruses. However, secreted and cell-associated forms of NS1
328 can be found, and both have varying immunogenic properties [18]. For instance, around 30% of
329 ZIKV- and DENV-reactive antibodies bind to NS1 [20,22]. Moreover, multiple studies have
330 shown a protective role of anti-NS1 against orthoflavivirus infection. As such, seminal work
331 showed that immunization with DENV-2 NS1 confers protection against a homologous DENV
332 infection in mice [40]. More recent studies obtained similar findings in mice immunized with a
333 ZIKV NS1-based vaccine. Specifically, this vaccine elicited high titers of protective antibodies,
334 and passive serum transfer from vaccinated mice conferred protection against lethal challenge [41].
335 In addition, antibodies directed to the cell-surface form of ZIKV NS1 may confer protection
336 against ZIKV infection during pregnancy by a mechanism related to complement deposition and
337 opsonization [26]. Similarly, monoclonal antibodies directed to the cell-surface form of West Nile
338 Virus NS1 activate Fcγ receptor-mediated phagocytosis and clearance of infected cells [42], while
339 anti-ZIKV NS1 antibodies promote antibody-dependent cellular toxicity [43,44]. On the other
340 hand, ZIKV NS1 induces placental dysfunction, increasing vascular permeability and spreading
341 the virus. Thus, anti-NS1 antibodies could also protect against ZIKV infection by decreasing the
342 immune evasion effects and placental dysfunction induced by the secreted form of NS1 [19,45].

343
344 The previous studies indicate a protective role of anti-NS1 homotypic antibodies. However, it is
345 unclear the role of anti-NS1 cross-reactive antibodies in individuals with pre-existing immunity to
346 DENV and subsequent ZIKV infection. In this regard, it is worth mentioning that the NS1 proteins
347 from DENV and ZIKV share some degree of homology [46,47], and some monoclonal antibodies
348 against DENV NS1 have cross-reactivity to ZIKV NS1 [48,49]. Importantly, these anti-DENV
349 NS1 cross-reactive antibodies can mediate protective effects against ZIKV NS1-induced
350 endothelial dysfunction [48], as well as decrease viral replication and cytokine production *in vitro*
351 [49]. In contrast, other studies have shown that the depletion of DENV-reactive antibodies in
352 serum does not significantly affect ZIKV neutralization [38,50], suggesting that type-specific
353 antibodies are responsible for most of this antibody-mediated protection. Considering the lack of
354 antibody-dependent enhancement of ZIKV infection by anti-NS1 antibodies [48], these studies
355 support the notion that cross-reactive antibodies targeting DENV NS1 may provide protection
356 against ZIKV infection and are a helpful vaccine target to prevent CZS.

357
358 In addition to the direct effects of anti-NS1 antibodies, they could be a surrogate of other immune
359 mechanisms of protection against CZS. For instance, ZIKV NS1-based immunization in

360 immunocompetent mice was recently shown to elicit high levels of anti-ZIKV NS1 antibodies.
361 However, T cell-mediated immunity, rather than anti-NS1 antibodies, is crucial for protecting
362 against the ZIKV challenge in this model [51]. Alternatively, efficient cooperation between anti-
363 DENV NS1 antibodies and CD4⁺ T cells may be required for optimal protection upon NS1-based
364 vaccination [52]. Moreover, the presence of antibodies to anti-ZIKV NS1 antibodies correlates
365 with the presence of ZIKV neutralizing antibodies, the latter probably being the direct protective
366 mechanism against infection [25]. In summary, anti-NS1 antibodies are an important arm of
367 humoral immunity against orthoflaviviruses. Their effector mechanisms and biological relevance
368 of homotypic and cross-reactive anti-NS1 antibodies in the setting of ZIKV infection and CZS
369 remain to be determined.

370

371 Several studies have documented neurodevelopment and ocular alterations in infants born to
372 mothers exposed to ZIKV during pregnancy, even in the absence of microcephaly [53,54].
373 However, the mechanisms behind this clinical entity in the setting of ZIKV infection are unknown
374 [55]. Here, we show that these neurological alterations differ respective to microcephaly in CZS
375 both in the time of ZIKV exposure and the association with placentally-transferred humoral
376 immunity. Likely, gestational ZIKV infection in the first trimester directly alters human brain cell
377 development [11], and low levels of protective anti-orthoflavivirus antibodies may predispose to
378 microcephaly. However, ZIKV infection beyond this time (when macroscopic brain architecture
379 has been already developed), along with maternal immune activation upon infection (which could
380 be indicated by the levels of anti-NS1 antibodies), may lead to changes in functional brain
381 connectivity and neurodevelopment alterations [56]. Novel studies should address the role of
382 maternal immune activation and orthoflavivirus humoral immunity in this setting.

383

384 Our study has some limitations. We did not prospectively measure antibody responses in pregnant
385 women early after ZIKV exposure, which could be better correlated with clinical outcomes in
386 newborns. However, the results of our study with a high number of mothers/children binomials
387 exposed to prenatal ZIKV infection support the utility of measuring orthoflavivirus humoral
388 immunity to identify individuals with increased risk of severe CZS in endemic areas. Furthermore,
389 it is important to note that children with microcephaly were older than those without this condition
390 at the time of sample analysis. This has implications for the levels of anti-NS1 antibodies.
391 However, the analysis of the DENV/ZIKV IgG-NS1 ratio (which is independent of the age of the
392 child) is useful to control this variable between both groups of individuals. Finally, a limitation of
393 our study is that the mechanisms behind the association found for IgG-NS1 antibodies and
394 microcephaly development were not explored. In this regard, at least two unanswered questions
395 remain to be addressed: which mechanisms are related to the association between anti-DENV NS1
396 antibodies and a good clinical outcome in CZS? Is the anti-NS1 IgG response a reflect of
397 homologous or heterologous neutralizing antibodies or virus-specific T cells playing a direct role
398 in protection against ZIKV infection?

399

400 In conclusion, here we show that the development of microcephaly in children with CZS is
401 associated with low plasma levels of placentally transferred, pre-existing DENV IgG-NS1
402 antibodies. These data align with the notion that the anti-orthoflavivirus NS1 IgG response may
403 play a protective role against ZIKV infection during pregnancy. These results have important
404 implications for the design of novel orthoflavivirus vaccine candidates and the identification of
405 correlates of protection. As such, an optimal anti-orthoflavivirus NS1 IgG response may be
406 required for adequate protection against prenatal ZIKV infection.

407

408 **Acknowledgments**

409 We thank the children and parents who kindly participated in this study and the Pediatric
410 Department of Hospital Universitario de Neiva, particularly Elisabeth Días. We also thank the
411 “Asociación Milagros de Dios” and Piedad Perilla for technical support.

412

413 **Funding information**

414 This study was supported by Universidad Surcolombiana, Vicerrectoría de Investigación grant
415 code 3660, and the MIT International Science and Technology Initiatives (MISTI)-Colombia.

416

417 **REFERENCES**

- 418 1. Gutiérrez-Bugallo G, Piedra LA, Rodríguez M, Bisset JA, Lourenço-de-Oliveira R, Weaver SC, et al.
419 Vector-borne transmission and evolution of Zika virus. *Nat Ecol Evol.* 2019;3: 561–569.
420 doi:10.1038/s41559-019-0836-z
- 421 2. Hasan SS, Sevana M, Kuhn RJ, Rossmann MG. Structural biology of Zika virus and other
422 flaviviruses. *Nat Struct Mol Biol.* 2018;25: 13–20. doi:10.1038/s41594-017-0010-8
- 423 3. WHO. Zika Virus. 2022 [cited 29 Apr 2024]. Available: [https://www.who.int/news-room/fact-](https://www.who.int/news-room/fact-sheets/detail/zika-virus)
424 [sheets/detail/zika-virus](https://www.who.int/news-room/fact-sheets/detail/zika-virus)
- 425 4. Pacheco O, Beltrán M, Nelson CA, Valencia D, Tolosa N, Farr SL, et al. Zika Virus Disease in
426 Colombia - Preliminary Report. *N Engl J Med.* 2020;383: e44. doi:10.1056/NEJMoa1604037
- 427 5. European Centre for Disease Prevention and Control. Rapid risk assessment: Microcephaly in
428 Brazil potentially linked to the Zika virus epidemic, 25 November 2015. 2015. Available:
429 [https://www.ecdc.europa.eu/en/publications-data/rapid-risk-assessment-microcephaly-brazil-](https://www.ecdc.europa.eu/en/publications-data/rapid-risk-assessment-microcephaly-brazil-potentially-linked-zika-virus-epidemic)
430 [potentially-linked-zika-virus-epidemic](https://www.ecdc.europa.eu/en/publications-data/rapid-risk-assessment-microcephaly-brazil-potentially-linked-zika-virus-epidemic)
- 431 6. Pierson TC, Diamond MS. The emergence of Zika virus and its new clinical syndromes. *Nature.*
432 2018;560: 573–581. doi:10.1038/s41586-018-0446-y

- 433 7. Freitas DA, Souza-Santos R, Carvalho LMA, Barros WB, Neves LM, Brasil P, et al. Congenital Zika
434 syndrome: A systematic review. *PLoS One*. 2020;15: e0242367-. Available:
435 <https://doi.org/10.1371/journal.pone.0242367>
- 436 8. N Costa MC, Cardim LL, Teixeira MG, Barreto ML, Carvalho-Sauer R de CO de, Barreto FR, et al.
437 Case Fatality Rate Related to Microcephaly Congenital Zika Syndrome and Associated Factors: A
438 Nationwide Retrospective Study in Brazil †. *Viruses*. 2020;12. doi:10.3390/v12111228
- 439 9. Cuevas EL, Tong VT, Rozo N, Valencia D, Pacheco O, Gilboa SM, et al. Preliminary Report of
440 Microcephaly Potentially Associated with Zika Virus Infection During Pregnancy — Colombia,
441 January–November 2016. *MMWR Morb Mortal Wkly Rep*. 2016. doi:10.15585/mmwr.mm6549e1
- 442 10. Tang H, Hammack C, Ogden SC, Wen Z, Qian X, Li Y, et al. Zika virus infects human cortical neural
443 progenitors and attenuates their growth. *Cell Stem Cell*. 2016. doi:10.1016/j.stem.2016.02.016
- 444 11. Garcez PP, Loiola EC, Madeiro da Costa R, Higa LM, Trindade P, Delvecchio R, et al. Zika virus
445 impairs growth in human neurospheres and brain organoids. *Science* (1979). 2016;352: 816–818.
446 doi:10.1126/science.aaf6116
- 447 12. Naveca FG, Pontes GS, Chang AY-H, Silva GAV da, Nascimento VA do, Monteiro DC da S, et al.
448 Analysis of the immunological biomarker profile during acute Zika virus infection reveals the
449 overexpression of CXCL10, a chemokine linked to neuronal damage. *Mem Inst Oswaldo Cruz*.
450 2018;113: e170542. doi:10.1590/0074-02760170542
- 451 13. Ornelas AMM, Pezzuto P, Silveira PP, Melo FO, Ferreira TA, Oliveira-Szejnfeld PS, et al. Immune
452 activation in amniotic fluid from Zika virus-associated microcephaly. *Ann Neurol*. 2017;81: 152–
453 156. doi:10.1002/ana.24839
- 454 14. Lum F-M, Low DKS, Fan Y, Tan JLL, Lee B, Chan JKY, et al. Zika Virus Infects Human Fetal Brain
455 Microglia and Induces Inflammation. *Clin Infect Dis*. 2017;64: 914–920. doi:10.1093/cid/ciw878
- 456 15. Priyamvada L, Suthar MS, Ahmed R, Wrammert J. Humoral Immune Responses Against Zika Virus
457 Infection and the Importance of Preexisting Flavivirus Immunity. *J Infect Dis*. 2017;216: S906–
458 S911. doi:10.1093/infdis/jix513
- 459 16. Sapparapu G, Fernandez E, Kose N, Cao B, Fox JM, Bombardi RG, et al. Neutralizing human
460 antibodies prevent Zika virus replication and fetal disease in mice. *Nature*. 2016;540: 443–447.
461 doi:10.1038/nature20564
- 462 17. Rathore APS, Saron WAA, Lim T, Jahan N, St. John AL. Maternal immunity and antibodies to
463 dengue virus promote infection and Zika virus–induced microcephaly in fetuses. *Sci Adv*. 2019.
464 doi:10.1126/sciadv.aav3208

- 465 18. Muller DA, Young PR. The flavivirus NS1 protein: molecular and structural biology, immunology,
466 role in pathogenesis and application as a diagnostic biomarker. *Antiviral Res.* 2013;98: 192–208.
467 doi:10.1016/j.antiviral.2013.03.008
- 468 19. Puerta-Guardo H, Tabata T, Petitt M, Dimitrova M, Glasner DR, Pereira L, et al. Zika Virus
469 Nonstructural Protein 1 Disrupts Glycosaminoglycans and Causes Permeability in Developing
470 Human Placentas. *J Infect Dis.* 2020;221: 313–324. doi:10.1093/infdis/jiz331
- 471 20. Stettler K, Beltramello M, Espinosa DA, Graham V, Cassotta A, Bianchi S, et al. Specificity, cross-
472 reactivity, and function of antibodies elicited by Zika virus infection. *Science.* 2016;353: 823–826.
473 doi:10.1126/science.aaf8505
- 474 21. Cavazzoni CB, Bozza VBT, Lucas TC V, Conde L, Maia B, Mesin L, et al. The immunodominant
475 antibody response to Zika virus NS1 protein is characterized by cross-reactivity to self. *J Exp*
476 *Med.* 2021;218. doi:10.1084/jem.20210580
- 477 22. Dejnirattisai W, Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana S, Limpitikul W, et al.
478 Cross-reacting antibodies enhance dengue virus infection in humans. *Science.* 2010;328: 745–
479 748. doi:10.1126/science.1185181
- 480 23. Fisher R, Lustig Y, Sklan EH, Schwartz E. The Role of NS1 Protein in the Diagnosis of Flavivirus
481 Infections. *Viruses.* 2023;15. doi:10.3390/v15020572
- 482 24. Bailey MJ, Duehr J, Dulin H, Broecker F, Brown JA, Arumemi FO, et al. Human antibodies targeting
483 Zika virus NS1 provide protection against disease in a mouse model. *Nat Commun.* 2018;9: 4560.
484 doi:10.1038/s41467-018-07008-0
- 485 25. Sornjai W, Ramphan S, Wikan N, Auewarakul P, Smith DR. High correlation between Zika virus
486 NS1 antibodies and neutralizing antibodies in selected serum samples from normal healthy Thais.
487 *Sci Rep.* 2019;9: 13498. doi:10.1038/s41598-019-49569-0
- 488 26. Wessel AW, Kose N, Bombardi RG, Roy V, Chantima W, Mongkolsapaya J, et al. Antibodies
489 targeting epitopes on the cell-surface form of NS1 protect against Zika virus infection during
490 pregnancy. *Nat Commun.* 2020;11: 5278. doi:10.1038/s41467-020-19096-y
- 491 27. Badolato-Corrêa J, Carvalho FR, Paiva IA, Familiar-Macedo D, Dias HG, Pauvolid-Corrêa A, et al.
492 Differential Longevity of Memory CD4 and CD8 T Cells in a Cohort of the Mothers With a History
493 of ZIKV Infection and Their Children. *Front Immunol.* 2021;12: 610456.
494 doi:10.3389/fimmu.2021.610456
- 495 28. Fialho EMS, Veras EM, Jesus CM de, Gomes LN, Khouri R, Sousa PS, et al. Maternal Th17 Profile
496 after Zika Virus Infection Is Involved in Congenital Zika Syndrome Development in Children.
497 *Viruses.* 2023;15. doi:10.3390/v15061320

- 498 29. Gutierrez-Barbosa H, Medina-Moreno S, Zapata JC, Chua J V. Dengue Infections in Colombia:
499 Epidemiological Trends of a Hyperendemic Country. *Trop Med Infect Dis.* 2020;5.
500 doi:10.3390/tropicalmed5040156
- 501 30. Visser L, Ruiters SAJ, Van der Meulen BF, Ruijsenaars WAJM, Timmerman ME. Validity and
502 suitability of the Bayley-III Low Motor/Vision version: a comparative study among young children
503 with and without motor and/or visual impairments. *Res Dev Disabil.* 2013;34: 3736–3745.
504 doi:10.1016/j.ridd.2013.07.027
- 505 31. Mejia-Wimar R, Veloza M, Rodríguez-Rodríguez J, Narváez C, Vega R, Salgado D, et al.
506 Neurodevelopmental follow-up of children with prenatal exposure to Zika virus. *Revista*
507 *Mexicana de Pediatría.* 2022;89: 246–253. doi:10.35366/111690
- 508 32. Salgado DM, Vega R, Rodríguez JA, Niño Á, Rodríguez R, Ortiz Á, et al. Clinical, laboratory and
509 immune aspects of Zika virus-associated encephalitis in children. *Int J Infect Dis.* 2020;90: 104–
510 110. doi:10.1016/j.ijid.2019.10.030
- 511 33. Castro-Trujillo S, Segura K, Bolívar-Marín S, Salgado DM, Bosch I, Vega R, et al. NS1-Specific
512 Antibody Response Facilitates the Identification of Children With Dengue and Zika in
513 Hyperendemic Areas. *Pediatr Infect Dis J.* 2024;43.
- 514 34. Cauchemez S, Besnard M, Bompard P, Dub T, Guillemette-Artur P, Eyrolle-Guignot D, et al.
515 Association between Zika virus and microcephaly in French Polynesia, 2013–15: a retrospective
516 study. *The Lancet.* 2016;387: 2125–2132. doi:https://doi.org/10.1016/S0140-6736(16)00651-6
- 517 35. Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in
518 healthy and pathological pregnancies. *Clin Dev Immunol.* 2012;2012: 985646.
519 doi:10.1155/2012/985646
- 520 36. Castanha PMS, Braga C, Cordeiro MT, Souza AI, Silva CDJ, Martelli CMT, et al. Placental Transfer
521 of Dengue Virus (DENV)-Specific Antibodies and Kinetics of DENV Infection-Enhancing Activity in
522 Brazilian Infants. *J Infect Dis.* 2016;214: 265–272. doi:10.1093/infdis/jiw143
- 523 37. Singh T, Lopez CA, Giuberti C, Dennis ML, Itell HL, Heimsath HJ, et al. Efficient transplacental IgG
524 transfer in women infected with Zika virus during pregnancy. *PLoS Negl Trop Dis.* 2019;13:
525 e0007648. doi:10.1371/journal.pntd.0007648
- 526 38. Andrade P, Gimblet-Ochieng C, Modirian F, Collins M, Cárdenas M, Katzelnick LC, et al. Impact of
527 pre-existing dengue immunity on human antibody and memory B cell responses to Zika. *Nat*
528 *Commun.* 2019. doi:10.1038/s41467-019-08845-3
- 529 39. Rodríguez-Barraquer I, Costa F, Nascimento EJM, Nery NJ, Castanha PMS, Sacramento GA, et al.
530 Impact of preexisting dengue immunity on Zika virus emergence in a dengue endemic region.
531 *Science.* 2019;363: 607–610. doi:10.1126/science.aav6618

- 532 40. Schlesinger JJ, Brandriss MW, Walsh EE. Protection of mice against dengue 2 virus encephalitis by
533 immunization with the dengue 2 virus non-structural glycoprotein NS1. *J Gen Virol.* 1987;68 (Pt
534 3): 853–857. doi:10.1099/0022-1317-68-3-853
- 535 41. Bailey MJ, Broecker F, Duehr J, Arumemi F, Krammer F, Palese P, et al. Antibodies Elicited by an
536 NS1-Based Vaccine Protect Mice against Zika Virus. *mBio.* 2019;10. doi:10.1128/mBio.02861-18
- 537 42. Chung KM, Thompson BS, Fremont DH, Diamond MS. Antibody recognition of cell surface-
538 associated NS1 triggers Fc-gamma receptor-mediated phagocytosis and clearance of West Nile
539 Virus-infected cells. *J Virol.* 2007;81: 9551–9555. doi:10.1128/JVI.00879-07
- 540 43. Sanchez Vargas LA, Adam A, Masterson M, Smith M, Lyski ZL, Dowd KA, et al. Non-structural
541 protein 1-specific antibodies directed against Zika virus in humans mediate antibody-dependent
542 cellular cytotoxicity. *Immunology.* 2021;164: 386–397. doi:10.1111/imm.13380
- 543 44. Lei Y, Xinglong L, Xianmiao Y, Wan S, Xiaoyan Z, Weiqi D, et al. Monoclonal Antibodies against
544 Zika Virus NS1 Protein Confer Protection via Fcγ Receptor-Dependent and -Independent
545 Pathways. *mBio.* 2021;12: 10.1128/mbio.03179-20. doi:10.1128/mbio.03179-20
- 546 45. Beatty PR, Puerta-Guardo H, Killingbeck SS, Glasner DR, Hopkins K, Harris E. Dengue virus NS1
547 triggers endothelial permeability and vascular leak that is prevented by NS1 vaccination. *Sci
548 Transl Med.* 2015;7: 304ra141-304ra141. doi:10.1126/scitranslmed.aaa3787
- 549 46. Chang H-H, Huber RG, Bond PJ, Grad YH, Camerini D, Maurer-Stroh S, et al. Systematic analysis of
550 protein identity between Zika virus and other arthropod-borne viruses. *Bull World Health Organ.*
551 2017;95: 517-525. doi:10.2471/BLT.16.182105
- 552 47. Wen J, Shresta S. Antigenic cross-reactivity between Zika and dengue viruses: is it time to
553 develop a universal vaccine? *Curr Opin Immunol.* 2019;59: 1–8.
554 doi:<https://doi.org/10.1016/j.coi.2019.02.001>
- 555 48. Biering SB, Akey DL, Wong MP, Brown WC, Lo NTN, Puerta-Guardo H, et al. Structural basis for
556 antibody inhibition of flavivirus NS1-triggered endothelial dysfunction. *Science.* 2021;371: 194–
557 200. doi:10.1126/science.abc0476
- 558 49. Sootichote R, Puangmanee W, Benjathummarak S, Kowaboot S, Yamanaka A, Boonnak K, et al.
559 Potential Protective Effect of Dengue NS1 Human Monoclonal Antibodies against Dengue and
560 Zika Virus Infections. *Biomedicines.* 2023;11. doi:10.3390/biomedicines11010227
- 561 50. Collins MH, McGowan E, Jadi R, Young E, Lopez CA, Baric RS, et al. Lack of Durable Cross-
562 Neutralizing Antibodies Against Zika Virus from Dengue Virus Infection. *Emerg Infect Dis.*
563 2017;23: 773–781. doi:10.3201/eid2305.161630

- 564 51. Grubor-Bauk B, Wijesundara DK, Masavuli M, Abbink P, Peterson RL, Prow NA, et al. NS1 DNA
565 vaccination protects against Zika infection through T cell-mediated immunity in
566 immunocompetent mice. *Sci Adv.* 2019;5: eaax2388. doi:10.1126/sciadv.aax2388
- 567 52. Gonçalves AJS, Oliveira ERA, Costa SM, Paes M V, Silva JFA, Azevedo AS, et al. Cooperation
568 between CD4+ T Cells and Humoral Immunity Is Critical for Protection against Dengue Using a
569 DNA Vaccine Based on the NS1 Antigen. *PLoS Negl Trop Dis.* 2015;9: e0004277-. Available:
570 <https://doi.org/10.1371/journal.pntd.0004277>
- 571 53. Tiene SF, Cranston JS, Nielsen-Saines K, Kerin T, Fuller T, Vasconcelos Z, et al. Early Predictors of
572 Poor Neurologic Outcomes in a Prospective Cohort of Infants With Antenatal Exposure to Zika
573 Virus. *Pediatr Infect Dis J.* 2022;41. Available:
574 [https://journals.lww.com/pidj/fulltext/2022/03000/early_predictors_of_poor_neurologic_outco
575 mes_in_a.24.aspx](https://journals.lww.com/pidj/fulltext/2022/03000/early_predictors_of_poor_neurologic_outcomes_in_a.24.aspx)
- 576 54. Einspieler C, Utsch F, Brasil P, Panvequio Aizawa CY, Peyton C, Hydee Hasue R, et al. Association
577 of Infants Exposed to Prenatal Zika Virus Infection With Their Clinical, Neurologic, and
578 Developmental Status Evaluated via the General Movement Assessment Tool. *JAMA Netw Open.*
579 2019;2: e187235–e187235. doi:10.1001/jamanetworkopen.2018.7235
- 580 55. Schuler-Faccini L, del Campo M, García-Alix A, Ventura LO, Boquett JA, van der Linden V, et al.
581 Neurodevelopment in Children Exposed to Zika in utero: Clinical and Molecular Aspects. *Front*
582 *Genet.* 2022;13. Available:
583 <https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2022.758715>
- 584 56. Spann MN, Monk C, Scheinost D, Peterson BS. Maternal Immune Activation During the Third
585 Trimester Is Associated with Neonatal Functional Connectivity of the Salience Network and Fetal
586 to Toddler Behavior. *The Journal of Neuroscience.* 2018;38: 2877. doi:10.1523/JNEUROSCI.2272-
587 17.2018
- 588
- 589
- 590
- 591
- 592
- 593
- 594
- 595

596

FIGURE LEGENDS

597 **Figure 1. Study flowchart.** ¹The plasma sample was taken after birth in the clinical follow-up.

598

599 **Figure 2. Placentally-transferred IgG-NS1. A-B.** Correlation analysis of the relative plasma
600 levels of ZIKV (A) and DENV1-4 (B) IgM-NS1 between mothers and children. **C-D.** Correlation
601 analysis of the relative levels of ZIKV (C) and DENV1-4 (D) IgG-NS1 between mothers and
602 children. **E-F.** Correlation and non-linear regression analysis of the relative levels of ZIKV (E)
603 and DENV1-4 (F) IgG-NS1 in relation to the children age. In all the cases, the *rho* and p-value of
604 the Spearman test are shown. The dashed lines indicate the ELISA limit of detection.

605

606 **Figure 3. Poor association between IgM-NS1 antibodies and CZS-related microcephaly. A**
607 **and C.** Frequency of ZIKV and DENV1-4 IgM-NS1 positivity rate in mothers (A) and children
608 (C) with or without microcephaly; Fisher's test. **B and D.** Relative levels of ZIKV and DENV1-4
609 IgM-NS1 in mothers (B) and children (D) with or without microcephaly; Mann-Whitney test. The
610 dashed lines indicate the ELISA limit of detection. NS: Not statistically significant. * $p < 0.05$.

611

612 **Figure 4. Association between IgG-NS1 antibodies and CZS-related microcephaly. A.**
613 Frequency of DENV1-4 IgG-NS1 positivity rate in mothers of children with or without
614 microcephaly. **B.** Relative plasma levels of ZIKV and DENV1-4 IgG-NS1 in mothers of children
615 with or without microcephaly. **C-D.** DENV1-4/ZIKV IgG-NS1 ratio in mothers of children
616 with or without microcephaly (C), and the respective ROC curve analysis (D). **E.** Frequency of ZIKV
617 and DENV1-4 IgG-NS1 positivity rate in children with or without microcephaly. **F.** Relative
618 plasma levels of ZIKV and DENV1-4 IgG-NS1 in children with or without microcephaly. **G-H.**
619 DENV1-4/ ZIKV IgG-NS1 ratio in children with or without microcephaly (G), and the respective
620 ROC curve analysis (H). In A and E, the p-value of the Fisher's test is shown. In B, C, F, and G,
621 the p-value of the Mann-Whitney test is shown. The dashed lines indicate the ELISA limit of
622 detection. NS: Not statistically significant. ** $p < 0.01$; *** $p < 0.001$.

623

624 **Supplementary Figure 1.** Comparison of the relative plasma levels of ZIKV and DENV1-4 IgM-
625 NS1 (A) and IgG-NS1 (B) in mothers and children. In all the cases, the positivity rate (PR) and
626 the p-value of the Mann-Whitney test are shown. The dashed lines indicate the ELISA limit of
627 detection. *** $p < 0.001$.

628


629 **Supplementary Figure 2.** Comparison of the relative plasma levels of ZIKV (**A** and **C**) and
630 DENV1-4 (**B** and **D**) IgG-NS1 in mothers (**A** and **B**) and children (**C** and **D**) after gestational ZIKV
631 exposure during the first or the third trimesters. In all the cases, the p-value of the Mann-Whitney
632 test is shown. The dashed lines indicate the ELISA limit of detection. NS: Not statistically
633 significant. **p<0.01

634


635 **Supplementary Figure 3.** Comparison of the relative plasma levels of ZIKV and DENV1-4 IgM-
636 NS1 (**A** and **C**) and IgG-NS1 (**B** and **D**) in mothers (**A** and **B**) and children (**C** and **D**) without
637 CZS, or those with neurodevelopment and ocular alterations. The p-value of Dunn's test is shown.
638 The dashed lines indicate the ELISA limit of detection. NS: Not statistically significant.
639 ***P<0.001

IgM-NS1 Orthoflavivirus (OD 450 nm)

A.




B.




medRxiv preprint doi: <https://doi.org/10.1101/2024.05.07.24306978>; this version posted May 7, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

IgG-NS1 Orthoflavivirus (OD 450nm)


C.




D.



E.




F.



● Mothers ● Children

Figure 2

Mother IgG-NS1 Orthoflavivirus



Children IgG-NS1 Orthoflavivirus




Figure 4








Figure 1

Mothers IgM-NS1 Orthoflavivirus



● No microcephaly ● Microcephaly

Figure 3